GRPH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 Mar 2024 @ 16:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
Today's Volume	299 406
Average Volume	40 955.00
Market Cap	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

Volume Correlation

Long: 0.15 (neutral)

Short: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. Correlation

10 Most Positive Correlations
SGLB	0.895
MTEX	0.893
ZENV	0.882
GRIN	0.88
PIII	0.874
RIVN	0.872
LCAP	0.868
SOPA	0.868
LAWS	0.865
OP	0.865

10 Most Negative Correlations
DYNT	-0.95
FTFT	-0.949
DGLY	-0.935
ATNX	-0.924
CRNC	-0.921
CFRX	-0.918
FGEN	-0.914
IPHA	-0.913
CSWI	-0.912
ECOR	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Graphite Bio, Inc. Correlation - Currency/Commodity

0.12
( neutral )

0.42
( neutral )

0.00
( neutral )

0.20
( neutral )

0.00
( neutral )

0.49
( neutral )

Graphite Bio, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.41M (0.00 %)
EPS:	$-2.19

Q4	2023
Revenue:	$10.24M
Gross Profit:	$10.09M (98.61 %)
EPS:	$-0.400

Q3	2023
Revenue:	$0
Gross Profit:	$-800 000 (0.00 %)
EPS:	$-0.390

Q2	2023
Revenue:	$0
Gross Profit:	$-2.10M (0.00 %)
EPS:	$-0.970

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.